Method of treating hepatitis delta virus infection

US6670342B2 · kind B2 · utility

Assignees

• Georgetown University · US
• Cornell Research Foundation, Inc. · US
• University of Georgia Research Foundation, Inc. · US

Inventors

• John L. Casey · Potomac, US
• Brent E. Korba · Laurel, US
• Paul J. Cote · Clifton Park, US
• John L. Gerin · Bethesda, US
• Bud Tennant · Ithaca, US
• Chung K. Chu · Statham, US

Key dates

• Filing date: Mar 29, 2001
• Grant date: Dec 30, 2003
• Expiry date: Mar 29, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/315
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.